An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

An Observational, Prospective Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix® 30 (Biphasic Insulin Aspart) Treatment

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions

Inclusion Criteria:

• Patients with Type 2 diabetes
• Insulin-naive or previously treated by basal only insulin therapy

Exclusion Criteria:

• Patients who are unlikely to comply with the protocol
• Pregnancy or breastfeeding or intention of becoming pregnant